Effects of sweet flavorings and nicotine on the appeal and sensory properties of e-cigarettes among young adult vapers: Application of a novel methodology.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this clinical trial publication.

Product characteristics that impact e-cigarette appeal by altering the sensory experience of vaping need to be identified to formulate evidence-based regulatory policies.

While products that contain sweet flavorings and produce a "throat hit" (i.e., desirable airway irritation putatively caused by nicotine) are anecdotally cited as desirable reasons for vaping among young adults, experimental evidence of their impact on user appeal is lacking.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, both men and women.

Participants rated appeal (liking, willingness to use again and perceived monetary value), perceived sweetness and throat hit strength after each administration.

How the Study Was Run

In design terms this was a double-blind, placebo-controlled and crossover study.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Electronic Nicotine Delivery Systems, Flavoring Agents, Multilevel Analysis, Nicotine, Vaping and Tobacco Products.

Author keywords: Appeal, Tobacco regulatory science and e-Cigarette.

What This Means in Plain Language

The paper is a double-blind, placebo-controlled and crossover study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Drug and alcohol dependence), a journal based in Ireland.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.